Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Recruiting, industry sponsors, Endocrinology and women's health, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed172
7 trials
Showing 1 to 7, recently updated first.
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT07909837 · 56 participants (planned) · Start Apr 23, 2026 · Primary completion Apr 2027
Drug: NTQ6179; NTQ6179 placebo · For: Acromegaly
Sites: Beijing, China
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Industry
NCT07755956 · 20 participants (planned) · Start Oct 31, 2026 · Primary completion Mar 31, 2027
Drug: HHK001; Enantone · For: Endometriosis
Sites: Changsha, China; Suzhou, China
- A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast CancerPivotal-lookingRecruiting
Rovi Pharmaceuticals LaboratoriesIndustry
NCT07401381 · 120 participants (planned) · Start Jun 8, 2026 · Primary completion May 2028
Drug: US-sourced oral Femara® + Letrozole SIE; EU sourced oral Femara® + Letrozole SIE · For: Hormone Receptor Positive Early Breast Cancer
Sites: Beverly Hills, California; Margate, Florida; Port Orange, Florida · 21 sites in all
- A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07264595 · 88 participants (planned) · Start Jan 18, 2026 · Primary completion Nov 2030
Drug: GS3-007a dry suspension; Placebo for GS3-007a dry suspension and 1 more · For: Pediatric Growth Hormone Deficiency
Sites: Wuhan, China
- A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal SubjectsPivotal-lookingRecruiting
Corium Innovations, Inc.Industry
NCT07794150 · 250 participants (planned) · Start Aug 10, 2026 · Primary completion May 31, 2027
Drug: Estradiol/Levonorgestrel Transdermal System · For: Menopause; Healthy Female Participants
Sites: Las Vegas, Nevada; Ahmedabad, India
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07016802 · 64 participants (planned) · Start Jun 9, 2025 · Primary completion Nov 25, 2026
Drug: GenSci134; Placebo and 1 more · For: Safety; Tolerability; Adult Growth Hormone Deficiency
Sites: Beijing, China
- Study of MAR002 in Healthy MenRecruiting
Marea TherapeuticsIndustry
NCT07195175 · 45 participants (planned) · Start Aug 11, 2025 · Primary completion Jul 2026
Drug: MAR002; Placebo · For: Acromegaly
Sites: Tempe, Arizona
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.